(S)-1-Boc-3-hydroxypiperidine is an important chiral intermediate for the synthesis of ibrutinib, an anticancer drug targeting B-cell malignancies. Synthesis of pharmaceutical intermediates including ibrutinib, the API of the newly approved drug Imbruvica, for the treatment of lymphoma.
(S)-1-Boc-3-hydroxypiperidine, alias (S)-N-Boc-3-hydroxypiperidine (S-NBHP) is an important chiral intermediate for the synthesis of ibrutinib, an anticancer drug targeting B-cell malignancies.S-NBHP can be prepared in a variety of ways such as chemically or biocatalytically. S-NBHP can be prepared in various ways, such as chemical synthesis or biocatalysis. Biocatalysis is an efficient process for the reduction of N-Boc-piperidin-3-one by recombinant keto reductase (KRED) catalytic to obtain optically pure S-NBHP using 99% yield. The asymmetric reduction of N-Boc-piperidin-3-one (NBPO) to (S)-NBHP can also be catalysed by a reductase (YDR541C) isolated from Saccharomyces cerevisiae in 99% yield.
A piperidine derivative with an amine protecting group, (S)-1-Boc-3-hydroxypiperidine can be used in the preparation of biologically active compounds such as antagonists of the human P2X7 receptor and selective irreversible inhibitors for bruton's tyrosine kinase.
(S)-1-Boc-3-hydroxypiperidine is used as pharmaceutical intermediate.
